麻豆传媒

E4Comfort II trial also found improvements in quality of life and markers of bone health

No association between earlier violence and processing speed, verbal memory

No adverse liver effects seen with elinzanetant in OASIS 3 trial

Meta-analysis of 23 randomized trials showed lower HOMA-IR

Despite renewed spotlight on menopause, use by insured still hasn't rebounded

Stigma, lack of employer support cited in Canadian survey study

Nighttime menopausal vasomotor symptoms linked to worse Alzheimer's biomarker profiles

These patients may be undertreated with hormone therapy, expert suggested

More than 10% of midlife women reported use to deal with stress, chronic pain, mood disturbances

Frequency, severity of vasomotor symptoms improved at week 12 with recently approved drug

Blood glucose, HbA1c also improved by week 12